Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global leader in eye health, has confirmed that discussions regarding the potential sale of the company to a third-party buyer have concluded without resulting in a transaction. The company had previously disclosed this potential sale process in December 2024, following a regulatory request.
In its latest statement, Bausch + Lomb clarified that “taking Bausch + Lomb private with a third-party buyer was one of several options being explored to complete a full separation from Bausch Health Companies Inc.” After thorough engagement with potential buyers, the process has now concluded, and no deal will proceed at this time.
Despite the end of the sale exploration, Bausch + Lomb reaffirmed its commitment to its goal of achieving a full separation from Bausch Health. “Full separation remains the goal,” the company stated. Bausch + Lomb will continue to operate independently, executing its established strategies and business plan.
The company also raised its 2024 revenue guidance on October 30 and will report its fourth-quarter and full-year 2024 earnings on February 19. Additionally, Bausch + Lomb will provide guidance for the 2025 fiscal year at that time.
Bausch + Lomb’s stock is traded on both the New York Stock Exchange and the Toronto Stock Exchange.
About Bausch + Lomb
Bausch + Lomb is a global eye health company dedicated to improving the gift of sight for millions of people worldwide. With a portfolio of approximately 400 products, the company offers a range of solutions, including contact lenses, lens care products, eye care treatments, ophthalmic pharmaceuticals, and surgical devices. Founded in 1853, Bausch + Lomb operates across nearly 100 countries and employs approximately 13,000 people. The company is headquartered in Vaughan, Ontario, with additional offices in Bridgewater, New Jersey.
Related topic:
Is There Surgery To Fix A Lazy Eye?
How To Get Rid Of Inflamed Eyelids?
3 Best Laser Eye Surgeries For Astigmatism
